<DOC>
	<DOCNO>NCT01554254</DOCNO>
	<brief_summary>Engraftment failure major obstacle success cord blood transplantation child malignancy inherit metabolic disorder , despite fact receive relatively high dos nucleate cell UCB . TXA127 pharmaceutically formulate Angiotensin 1-7 [ A ( 1-7 ) ] , non-hypertensive derivative Angiotensin-II ( contain 8th amino acid confer receptor bind blood pressure receptor ) . TXA127 multilineage effect hematopoietic progenitor vitro vivo . Preclinical data show TXA127 novel stimulator early multilineage hematopoietic progenitor , increase engraftment commit hematopoietic progenitor , induces rapid production platelet neutrophils peripheral circulation , especially limited cell number transplant . Treatment TXA127 follow UCBT expect increase number hematopoietic progenitor accelerate engraftment .</brief_summary>
	<brief_title>Evaluation Safety Efficacy TXA127 ( Angiotensin 1-7 ) Enhance Engraftment Pediatric Patients Undergoing Single Double Umbilical Cord Blood Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Angiotensin I ( 1-7 )</mesh_term>
	<criteria>Subject , parent , legal guardian provide write informed consent . Subjects must &gt; 6 month &lt; 21 year age . Subjects must one two available 4 , 5 , 6/6 antigen matching unrelated UCB unit ( ) deliver cell dose 3.05.0 x 107cells/kg . These unit must HLAmatched minimally 4 6 HLAA B ( intermediate resolution molecular typing ) DRB1 ( high resolution molecular typing ) locus subject . If two CB unit use , unit must HLAmatched 3 6 HLA A , B , DRB1 locus ( use resolution molecular typing indicate ) . For single unit transplant , minimum 3 x 107cells/kg require . For double unit transplant , HLAmatched unit must available together unit deliver combine precryopreserved nucleate cell dose least 4.0 x 107 cells/kg 1 unit least 2.5 x 107 cells/kg least 1.5 x 107 cells/kg . Subjects must histologically confirm diagnosis hematologic malignancy laboratory confirm inherit metabolic disease . Subjects prior autologous allogeneic transplant allow participate provide &gt; 1 year since transplant complete . Subjects must active CNS disease time study enrollment . Subjects must life expectancy &gt; 4 month . Female subject capable reproduction ( define subject start menses ) must agree follow : Use effective oral IM contraceptive method course study 2 month follow last administration study drug . Female subject capable reproduction must negative pregnancy test result within 3 day prior first study drug dose . Subjects must adequate function organ system measure : Creatinine &lt; 2.0 mg/dL creatinine clearance &gt; 50 mL/min . Hepatic transaminase ( ALT/AST ) &lt; 4 x ULN , bilirubin &lt; 2.0 mg/dL . Adequate cardiac function echocardiogram MUGA scan ( ejection fraction shorten fraction &gt; 80 % normal value age ) . Pulmonary function test demonstrate FVC FEV1 &gt; 60 % predict . DLCO use subject &gt; 10 year old . Crying vital capacity &gt; 60 % may substitute subject unable complete PFTs . Subjects uncontrolled infection time cytoreduction . Subjects pregnant breast feeding . Subjects know seropositive HIV HTLV1 . Subjects autologous allogeneic transplant &lt; 1 year anticipate administration first dose study drug . Subjects receive treatment investigational agent within 30 day anticipate administration first dose study drug . Subjects current alcohol use , illicit drug use condition ( e.g. , psychiatric disorder ) , opinion Investigator , may interfere subject 's ability comply study requirement visit schedule . Subjects must comorbid condition , view Principal Investigators , render subject high risk treatment complication regimenrelated morbidity/mortality .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cord blood transplant</keyword>
	<keyword>hematological malignancy</keyword>
	<keyword>inherit metabolic disease</keyword>
	<keyword>Mucositis</keyword>
	<keyword>Neutrophil engraftment</keyword>
	<keyword>Platelet recovery</keyword>
	<keyword>Immune reconstitution</keyword>
</DOC>